Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.

Abstract

The role of steroidal inhibitors of androgen biosynthesis as potential weapons in the treatment of prostatic diseases, such as benign prostatic hyperplasia and prostatic cancer will be reviewed. Two enzymes have been targeted in the development of inhibitors that potentially could be useful in the management of such conditions. 5α-Reductase is primarily of interest in benign prostatic disease, though some role in the chemoprevention of prostatic carcinoma have been considered, whereas the 17α-hydroxylase/17,20-lyase (CYP17) enzyme is of interest in the treatment of malignant disease. An overview of the main achievements obtained during the past years will be presented, however special focus will be made on steroidal molecules that reached clinical trials or have been commercially launched. Relevant examples of such drugs are finasteride, dutasteride, abiraterone acetate and galeterone (TOK-001, formerly known as VN/124-1). This article is part of a Special Issue entitled "Synthesis and biological testing of steroid derivatives as inhibitors".

• Authors: Jorge A R Salvador, Rui M A Pinto, Samuel M Silvestre
• Journal: The Journal of steroid biochemistry and molecular biology (J Steroid Biochem Mol Biol) Vol. 137 Pg. 199-222 (Sep 2013) ISSN: 1879-1220 [Electronic] England
• PMID: 23688836 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• 5-alpha Reductase Inhibitors
• Enzyme Inhibitors
• Steroid 17-alpha-Hydroxylase

Topics

• 5-alpha Reductase Inhibitors (pharmacology, therapeutic use)
• Enzyme Inhibitors (pharmacology, therapeutic use)
• Humans
• Male
• Prostatic Hyperplasia (drug therapy, enzymology)
• Prostatic Neoplasms (drug therapy, enzymology)
• Steroid 17-alpha-Hydroxylase (antagonists & inhibitors)